Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease.

Reed BY, Masoumi A, Elhassan E, McFann K, Cadnapaphornchai MA, Maahs DM, Snell-Bergeon JK, Schrier RW.

Kidney Int. 2011 Jan;79(1):128-34. doi: 10.1038/ki.2010.355. Epub 2010 Sep 29.

2.

Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.

Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF Jr, Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.

Kidney Int. 2003 Sep;64(3):1035-45.

3.

Angiogenesis in autosomal-dominant polycystic kidney disease.

Bello-Reuss E, Holubec K, Rajaraman S.

Kidney Int. 2001 Jul;60(1):37-45.

4.

Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.

King BF, Torres VE, Brummer ME, Chapman AB, Bae KT, Glockner JF, Arya K, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Kidney Int. 2003 Dec;64(6):2214-21.

5.

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.

Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15.

PMID:
25600953
6.

Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.

Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, van der Jagt EJ, van Goor H, Peters DJ, Navis G, de Jong PE, Gansevoort RT.

Am J Kidney Dis. 2010 Nov;56(5):883-95. doi: 10.1053/j.ajkd.2010.06.023.

PMID:
20888104
7.

Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.

Raina R, Lou L, Berger B, Vogt B, Do AS, Cunningham R, Vasavada P, Herrmann K, Dell K, Simonson M.

BMC Nephrol. 2016 Feb 29;17:22. doi: 10.1186/s12882-016-0232-8.

8.

Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.

Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM.

Nephrol Dial Transplant. 2013 Feb;28(2):380-5. doi: 10.1093/ndt/gfs417. Epub 2012 Dec 4.

9.

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS.

Kidney Int. 2011 Aug;80(3):295-301. doi: 10.1038/ki.2011.119. Epub 2011 May 4.

10.

Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.

Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW.

Clin J Am Soc Nephrol. 2014 May;9(5):889-96. doi: 10.2215/CJN.08350813. Epub 2014 Apr 10.

11.

Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.

Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ.

Clin J Am Soc Nephrol. 2012 Mar;7(3):479-86. doi: 10.2215/CJN.09500911. Epub 2012 Feb 16.

12.

Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease.

Bae K, Park B, Sun H, Wang J, Tao C, Chapman AB, Torres VE, Grantham JJ, Mrug M, Bennett WM, Flessner MF, Landsittel DP, Bae KT; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2013 Jul;8(7):1089-97. doi: 10.2215/CJN.10561012. Epub 2013 Mar 21.

13.

Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease.

Zheng D, Wolfe M, Cowley BD Jr, Wallace DP, Yamaguchi T, Grantham JJ.

J Am Soc Nephrol. 2003 Oct;14(10):2588-95.

14.

Angiogenesis and autosomal dominant polycystic kidney disease.

Huang JL, Woolf AS, Long DA.

Pediatr Nephrol. 2013 Sep;28(9):1749-55. doi: 10.1007/s00467-012-2305-7. Epub 2012 Sep 19. Review.

PMID:
22990303
15.

Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies.

Chapman AB.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1197-204. doi: 10.2215/CJN.00060108. Epub 2008 Jun 25. Review.

16.

Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.

Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2007 Jan;2(1):112-20. Epub 2006 Nov 2.

17.

Abdominal sonographic study of autosomal dominant polycystic kidney disease.

Nicolau C, Torra R, Bianchi L, Vilana R, Gilabert R, Darnell A, BrĂș C.

J Clin Ultrasound. 2000 Jul-Aug;28(6):277-82.

PMID:
10867665
19.
20.

Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease.

Helal I, Reed B, McFann K, Yan XD, Fick-Brosnahan GM, Cadnapaphornchai M, Schrier RW.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2439-43. doi: 10.2215/CJN.01010211. Epub 2011 Sep 8.

Supplemental Content

Support Center